The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] …
Category: Research/Reports
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...] …
A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...] …
As the not-for-profit hospital sector slowly emerges from its worst financial year in recent history, some of those organizations’ bottom [...] …
The 340B drug pricing program may incentivize hospitals and other covered entities to buy expensive preventative HIV medications over low-cost [...] …
The 340B drug pricing program has evolved from a “buy low, sell low” program to help safety-net hospitals serve low-income [...] …
Early, limited versions of contract pharmacy restrictions for 340B hospitals cut their revenue by $1.5 billion in one year, according [...] …
Two new studies—one by pharmacists at Ascension Via Christi health system in Kansas, the other by drug industry consulting and [...] …
A new “playbook” for employers on getting the upper hand with pharmacy benefit managers says PBM handling of 340B drugs is a top 10 concern for business-sponsored health plans.
Released yesterday by the Washington, D.C., based National Alliance of Healthcare
…Hospitals that enrolled in the 340B program after its expansion in 2010 treated more commercially insured cancer patients with five commonly prescribed biologic oncology drugs and spent more on the drugs, a new JAMA study found.
The authors of …